

## Antithrombotic Lipid Minor Constituents from Vegetable Oils. Comparison between Olive Oils and Others

HARALABOS C. KARANTONIS,<sup>†</sup> SMARAGDI ANTONOPOULOU,<sup>\*,‡</sup> AND  
CONSTANTINOS A. DEMOPOULOS<sup>†</sup>

Faculty of Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis,  
15771 Athens, Greece, and Department of Science of Nutrition-Dietetics,  
Harokopio University of Athens, 17671 Athens, Greece

Many epidemiological studies suggest that vegetable oils and especially olive oil present a protective effect against atherosclerosis. In this study, total lipids (TL) of Greek olive oils and seed oils of four kinds, namely, soybean, corn, sunflower, and sesame oil, were separated into total polar lipids (TPL) and total neutral lipids (TNL) via a novel extraction procedure. TPL and TNL of olive oil were fractionated by HPLC for further study. Each lipid fraction from HPLC separation along with TL, TPL, and TNL lipid samples from oils were tested in vitro for their capacity to induce or to inhibit washed rabbit platelet aggregation. Comparison between olive and seed oils supports the superiority of olive oil as high levels of platelet activating factor (PAF) antagonists have been detected, mainly in TPL. In addition, the structure of the most active fraction from olive oil was elucidated, as a glycerol–glycolipid. Because it has already been reported that PAF plays a pivotal role in atherogenesis, the existence of PAF agonists and antagonists in vegetable oils may explain their protective role against atherosclerosis.

**KEYWORDS:** Olive oil; sesame oil; corn oil; soybean oil; sunflower oil; bioactive lipids; high-performance liquid chromatography; Mediterranean diet; platelet activating factor; atherogenesis

### INTRODUCTION

Vegetable oils and especially olive oil are traditionally considered to be basic components of the Mediterranean diet, which exhibits a protective effect against coronary heart disease. Regional cardiovascular morbidity and mortality data of the Western hemisphere show a particularly low prevalence in the Mediterranean region (1). Furthermore, epidemiological studies have shown a correlation between diet and the incidence of coronary heart disease (CHD). A lower incidence of CHD in Mediterranean countries has been correlated with the so-called Mediterranean diet, which is rich in vegetables, grains, legumes, fruits, and vegetable oils, mainly olive oil (2, 3). Results from many clinical, experimental, and epidemiological studies are in accordance with this correlation (4). Thus, the Mediterranean diet has been suggested to reduce the incidence of CHD. The role of dietary lipids is being intensely studied by many authors, with regard to not only the amount but also the quality of the dietary fat. Thus, vegetable oils are considered to have anti-atherogenic effects (5, 6).

Furthermore, it is proved that oxidatively modified low-density lipoproteins (ox-LDLs) become cytotoxic to endothelial

cells and chemotactic for monocytes and exhibit an increased affinity for their scavenger receptor, thus stimulating the formation of foam cells loaded with cholesterol esters (7). These processes affect the structure and function of the intima and lead to the formation of atherosclerotic plaques. On the other hand, the response to injury hypothesis explains atherosclerosis as a chronic inflammatory response to injury of the endothelium, where complex cellular and molecular interactions are taking place among blood cells and cells derived from the endothelium (8, 9).

As we previously described, we propose a mechanism by which platelet activating factor (PAF) (10) is implicated in atheromatosis generation (11) on the basis of the previous detection of PAF, which is produced during LDL oxidation (12) and causes in situ inflammation. This mechanism is further supported because PAF not only is the strongest inflammatory lipid mediator and is present as a constituent of atheromatic plaque but also is essential for the activation of leukocytes and their binding in the endothelial cells, which are critical events in atherogenesis (13). Furthermore, PAF antagonists exhibit protective action against atheromatosis generation (14, 15) and PAF–acetylhydrolase, the main enzyme responsible for the degradation of PAF, exhibits reduced activity in ox-LDL relative to unmodified LDL (12).

Therefore, the detection of lipid compounds in Mediterranean foods, which inhibit PAF action, could explain their protective

\* Address correspondence to this author at 14 Messinias Str., Athens GR-15234, Greece (telephone 003010 9549305; fax 003010 9577050; e-mail antonop@hua.gr).

<sup>†</sup> National and Kapodistrian University of Athens.

<sup>‡</sup> Harokopio University of Athens.

effect against atheromatosis generation. Until now the reported studies, although in general exhaustive, have focused mostly on fatty acids of vegetable oils (16). Other compounds that exist as microconstituents in vegetable oils are tocopherols, flavonoids, anthocyanins, hydroxy- and dihydroxyterpenic acids, sterols, phenolic constituents, and phospholipids. The amount of these compounds depends on various conditions such as climate, degree of ripeness of the fruit, and its handling (17). These compounds are also present in lower concentrations in low-quality oils, characterized by a high degree of acidity, that are subjected to further refining (18). Although there are a number of studies concerning some of these constituents (19–21), there are no studies concerning the bioactivity of phospholipids and glycolipids of vegetable oils. Moreover, studies have been generally restricted to changes in lipids and lipoproteins, without examining factors related to the thrombotic risks such as platelet aggregation. There is, however, still no adequate basis to explain a direct influence of any nutrient intake on the low cardiovascular mortality in this region.

The effect of dietary fat on plasma lipid concentration, especially on the cholesterol level, has also been extensively studied (22–24). One of the most important reasons for all of these studies is that hypercholesterolemia is thought to be an important cause of coronary heart disease (25). However, high cholesterol levels seem to play a secondary role because even the same cholesterol level can result in an important variation in the clinical expression of the disease (26). Furthermore, although there is a similar distribution of other coronary risk factors such as high blood pressure, serum cholesterol, body mass index, and cigarette smoking, the mortality due to CHD is lower in Crete, where the population follows a traditionally Cretan Mediterranean diet (27). Previous studies in our laboratory demonstrated the existence of compounds that inhibit PAF aggregatory action in olive oil (28), honey (29), milk and yogurt (30), fish (31), and red wine (32).

The interest in research on the biological effects of lipid extracts from vegetable oils, such as their ability to antagonize factors such as PAF and thrombin on platelet aggregation and the importance of these dietary compounds in the prevention of CHD, prompted us to investigate the effects of total, neutral, and polar lipids from vegetable oils, before and after separation and purification with HPLC, on platelet aggregation. It is a real challenge and absolutely necessary to determine the biologically active lipid microconstituents in order to understand not only their bioactivities and possible side effects but also mechanisms of pathophysiological conditions such as atherogenesis, which remain an unresolved controversy.

This work aims to evaluate the bioactivity of lipid fractions of various kinds of vegetable oils and to elucidate the structure of bioactive lipids. The results of this study raise the question of whether total lipid bioactivity could serve as a nutritional index.

## MATERIALS AND METHODS

**Instrumentation.** The separation of lipids was performed at room temperature on an HP HPLC series 1100 liquid chromatograph model (Hewlett-Packard, Waldbronn, Germany) equipped with a 100  $\mu$ L loop Rheodyne (7725 i) loop valve injector, a degasser G1322A, a quaternary gradient pump G1311A, and an HP UV spectrophotometer G1314A as a detection system. The spectrophotometer was connected to a Hewlett-Packard model HP-3395 integrator–plotter. Neutral lipids were separated on a Nucleosil-300 7  $\mu$ m C-18 reverse column (250  $\times$  4.6 mm i.d.) from Analysentechnik (Wöhlerstrasse, Mainz, Germany) with a C-18 ODS (20  $\times$  4.0 mm i.d.) precolumn cartridge. For the separation of the polar lipids was used either a Partisil 10  $\mu$ m SCX

Table 1. Samples of Vegetable Oils

olive oil	extraction procedure	source (location)
1	pressing	Belika Messinis
2	centrifugal	Maurolia
3	centrifugal	St. Sotiria Messinis
4	pressing	Batsikes
5	two phases	Kalamata
6	pressing	Kalamata
7	two phases	Kalamata
8	centrifugal	St Pelagia
9	centrifugal	Trifillias town
10	centrifugal	Kalamata
11	centrifugal	Kalamata
12	centrifugal	Koukounara

seed oil	type	source
1	soybean	Minerva
2	corn	Elais
3	corn	Minerva
4	sunflower	Minerva
5	sunflower	Elais
6	sesame	Limnos Area (Axiladelis)

column (250  $\times$  4.6 mm i.d.) from Analysentechnik with an SCX (20  $\times$  4.0 mm i.d.) precolumn cartridge or a Spherclone 5u NH<sub>2</sub> normal phase column (250  $\times$  4.6 mm i.d.) from Phenomenex (Huntsfield, Cheshire, U.K.) with an NH<sub>2</sub> silica (20  $\times$  4.0 mm i.d.) precolumn cartridge and a Kromasil 100 5  $\mu$ m silica column (250  $\times$  4.6 mm) from Analysentechnik with a silica precolumn cartridge (20  $\times$  4.0 mm i.d.). Radioactivity was measured in a 1209 RackBeta-Flexivial  $\beta$ -counter (LKB-Pharmacia, Turku, Finland). PAF-induced aggregation was measured in a Chrono-Log (Havertown, PA) aggregometer coupled to a Chrono-Log recorder. Electrospray ionization (ESI) mass spectrometry experiments were performed on a Q-ToF (Micromass U.K. Ltd., Manchester, U.K.) orthogonal acceleration quadrupole time-of-flight mass spectrometer equipped with nano-electrospray ionization and purchased with funding from the BBSRC, the University of Leeds, and Micromass U.K. Ltd.

**Materials.** All reagents and chemicals were of analytical grade supplied from Merck (Darmstadt, Germany). The solvents used for high-performance liquid chromatography (HPLC) were purchased from Ruthburn (Walkerburn, Peebleshire, U.K.). All standards were obtained from Sigma (St. Louis, MO). Semisynthetic PAF (80% C-16PAF and 20% C-18PAF) was synthesized in our laboratory as previously described (10). [<sup>3</sup>H]PAF (NET 910) was purchased from NEN (DuPont, Boston, MA). PAF–acetylhydrolase from human serum was purified according to the method of Stafforini et al. (33). Bovine serum albumin (BSA), creatine phosphate (CP)/creatine phosphate kinase (CPK), BN 52021, and indomethacin were obtained from Sigma. Olive oil samples extracted via different procedures were all of the Koroneiki variety from Kalamata and its surrounding area, whereas seed oils were from eponymic oil industries with the exception of sesame oil, which was from Limnos Island (Table 1).

**Separation of Total Lipids to Polar and Neutral Lipids.** The vegetable oils in the form just as they were purchased are considered as total lipids. Their separation to polar and neutral lipids (Figure 1) was achieved with a modification of the countercurrent distribution extraction procedure of Galanos and Kapoulas (34). Polar lipids contained mainly phospholipids and some glycolipids. The distribution is carried out in three separatory funnels by the single withdrawal procedure (35). That is, an amount of vegetable oil is diluted in a quadruple volume of petroleum ether (bp 40–70 °C) pre-equilibrated with ethanol. This constitutes the initial total volume. The solution is transferred to a separatory funnel and shaken with one-fifth of the total initial volume, ethanol 87% (lower phase), pre-equilibrated with petroleum ether. After 5 min, the two phases are separated, and in the equilibrated upper phase of petroleum ether (oil), ethanol in an amount of one-fifth of the total initial volume is added. Both the equilibrated lower phase and ethanol are transferred to a second funnel, and petroleum ether in an amount of two-fifths of the total initial volume





**Table 2.** IC<sub>50</sub> Values of TL and TNL from Olive Oils and Seed Oils

sample	IC <sub>50</sub> TL <sup>a</sup> (μL)	IC <sub>50</sub> TNL (μL)	initial vol (μL) for shape change (TL act.)
Olive Oils			
1	0.175	0.120	nd <sup>b</sup>
2	0.118	0.141	0.200
3	0.250	0.207	0.200
4	0.172	0.114	0.150
5	0.185	0.214	0.150
6	0.202	0.162	0.150
7	0.278	0.136	0.150
8	0.180	0.153	0.200
9	0.185	0.086	nd
10	0.178	0.140	nd
11	0.140	0.123	nd
12	0.210	0.147	nd
Seed Oils			
1	0.832	0.096	nd
2	0.470	0.088	nd
3	0.165	0.112	nd
4	0.440	0.147	nd
5	0.128	0.080	0.300
6	0.168	0.108	nd

<sup>a</sup> Values are expressed in microliters of initial volume of oil which induces 50% inhibition against  $1 \times 10^{-11}$  M PAF, final concentration. <sup>b</sup> Not detected.

Nitrogen was employed as the drying gas. The microchannel plate detector was set at 2850 V.

Tandem mass spectrometric (MS/MS) studies were performed by selecting a precursor ion with the first (quadrupole) analyzer. These ions were transmitted to a collision cell, where they were bombarded with argon gas at an energy of 10–50 eV. The resulting fragment ions were *m/z* analyzed by the second (time-of-flight) analyzer.

Data were acquired over the appropriate *m/z* range and spectra processed using the MassLynx software supplied with the mass spectrometer.

## RESULTS AND DISCUSSION

**Separation and Biological Activity of Total Lipid Fractions.** The procedure for the separation of TL to TPL and TNL as well as the general experimental strategy is shown in **Figure 1**. An amount of total lipids (TL) was kept for testing biological activity; the rest was separated in neutral and polar lipids according to the modified countercurrent distribution extraction procedure. By this procedure the total polar lipid fraction contained glyco- and phospholipids. The recovery of the method was estimated to be 96% by the addition of [<sup>3</sup>H]PAF and the measurement of radioactivity at the polar lipid fraction after the extraction procedure.

An amount of the total lipid fractions (TL, TPL, TNL), of the 12 olive oils and the 6 seed oils was tested for its ability either to induce or to inhibit PAF-induced washed rabbit platelet aggregation. All TL and TNL caused inhibition of PAF-induced washed rabbit platelet aggregation, in a dose-dependent manner. TL but not TNL of the majority of olive oil samples as well as TL of sunflower oil (Elais) caused, in specific amounts, shape change of platelets (**Table 2**). Because TNL had effects on washed rabbit platelets similar to those of TL, the results indicate that the shape change was caused by TPL, which may have significant biological activity. Indeed, TPL from all olive oil samples exhibited inhibitory activity against PAF action, in a dose-dependent manner, up to a certain amount, whereas larger amounts caused aggregation of platelets (**Table 3**). TPL from seed oil samples also caused dose-dependent inhibition of PAF action. Larger amounts caused total inhibition except soybean oil, which caused shape change of platelets, and sesame oil,

**Table 3.** IC<sub>50</sub> and C<sub>PAF</sub> Values of TPL from Olive and Seed Oils

olive oil	IC <sub>50</sub> <sup>a</sup>	initial vol (μL) that induces aggregation	C <sub>PAF</sub> × 10 <sup>-11</sup> M <sup>b</sup>
1	16.2	75	8.2
2	162	312	14
3	12.5	162	7.3
4	9.38	138	34
5	12.2	375	11
6	8.12	250	10
7	11.8	250	15
8	7.00	150	3
9	17.5	462	11
10	11.1	375	6.5
11	6.25	88	11
12	6.25	150	15

seed oil	IC <sub>50</sub>	initial vol (μL) that exerts bioactivity	bioactivity
1	138	1125	shape change
2	255	1125	<i>f</i> : 100%
3	362	1125	<i>t</i> : 100%
4	125	1125	<i>t</i> : 100%
5	100	1125	<i>t</i> : 100%
6	7.5	625	<i>A</i> <sup>d</sup> : C <sub>PAF</sub> = $6.2 \times 10^{-11}$ M


<sup>a</sup> Values are expressed in microliters of initial volume of oil that induces 50% inhibition against  $1 \times 10^{-11}$  M PAF, final concentration. <sup>b</sup> Concentration of PAF that exhibits the same aggregatory activity as indicated in the table amount (in microliters) of initial volume of oil. <sup>c</sup> Inhibition of platelet aggregation induced by  $1 \times 10^{-11}$  M PAF, final concentration. <sup>d</sup> Aggregation of washed rabbit platelets.

which exhibited aggregatory activity on platelets (**Table 3**). These results indicated the existence of microconstituents in TPL of vegetable oils, especially of olive oils that act as PAF antagonists. Although all vegetable oils tested presented biological activity, the above results showed that olive oil samples were more bioactive than seed oils, with the exception of sesame oil. This superiority seems to be due to TPL. Furthermore, these findings raised the question of whether TL bioactivity could be used as a nutritional index.

Although statistical data cannot be presented because of the small number of samples that pertain to the same category, results pointed out the above significant conclusions since the scope of the present work was to investigate the bioactivity of certain fractions of vegetable oils and to elucidate structures of unidentified lipid microconstituents. The identification of such compounds may be of help to the field of nonsteroidal anti-inflammatory drugs as well as to the understanding of various metabolic paths concerning serious pathophysiological conditions. The greater bioactivity of olive oils in total polar lipids (TPL) prompted us to further investigate an olive oil sample.

**Separation and Biological Activity of Olive Oil Polar Lipid on an SCX Column.** The amount of total polar lipid fraction from 10 mL of olive oil, after evaporation in a vacuum on a rotary evaporator and dilution in chloroform/methanol (1:1), was fractionated (36) in five sequential separations of 100 μL each (**Figure 2**). Fractions of the same retention times from each separation were pooled together to give nine fractions, which were tested for their biological activities.

Seven of the nine fractions caused inhibition of platelet aggregation against  $1 \times 10^{-11}$  M PAF. The results are shown in **Table 4**. Fractions 3–5, which were the most potent PAF inhibitors, were also tested for their inhibitory activity against thrombin-induced washed rabbit platelet aggregation in the IC<sub>50</sub> amount expressed as initial volume of olive oil. These fractions



**Figure 2.** Representative HPLC chromatogram of total polar lipids (TPL) of olive oil on an SCX column. Conditions and elution of phospholipid standards were as indicated. PE, phosphatidylethanolamine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin; PAF, platelet activating factor; LPC, lysophosphatidylcholine; GL, glycolipids; numbers 1–9 above the x-axis refer to the collected fractions.

**Table 4.**  $IC_{50}$  and  $C_{PAF}$  Values of Polar Lipid Fractions from Olive Oil after Separation on an SCX Column

polar lipid fraction	$IC_{50}^a$	standards eluted in the same time
1	2499	between PE <sup>b</sup> and LPE <sup>c</sup>
2	3123	same with LPE
3	437.5	between LPE and PC <sup>d</sup>
4	162.5	between LPE and PC
5	375.0	between PC and SM <sup>e</sup>
6	637.5	between PC and SM
9	1000	beyond LPC <sup>f</sup>

polar lipid fraction	$\mu\text{L}$	$C_{PAF} \times 10^{-11} \text{ M}^g$	standards eluted in the same time
7	375	3.5	same with PAF <sup>h</sup>
	562	5.8	
8	1125	3.2	same with LPC

<sup>a</sup> Values are expressed in microliters of initial volume of oil that induces 50% inhibition against  $1 \times 10^{-11}$  M PAF, final concentration. <sup>b</sup> Phosphatidylethanolamine. <sup>c</sup> Lysophosphatidylethanolamine. <sup>d</sup> Phosphatidylcholine. <sup>e</sup> Sphingomyelin. <sup>f</sup> Lysophosphatidylcholine. <sup>g</sup> Concentration of PAF that exhibits the same aggregatory activity as indicated in table amount (in microliters) of initial volume of oil. <sup>h</sup> Platelet activating factor.

were more active inhibitors of thrombin; they caused 100, 80, and 100% inhibition of thrombin activity, respectively.

Two of the above fractions (fractions 7 and 8) caused aggregation of the platelets. The aggregatory activity of fraction 7, which was the most active, was dose-dependent. This fraction desensitized  $1 \times 10^{-11}$  M PAF (final concentration) at 100% in an amount of 375  $\mu\text{L}$  (initial volume of oil), and it also desensitized thrombin (0.025 unit/cuvette) at 100% in an amount of 562  $\mu\text{L}$ .

**Separation and Biological Activity of Olive Oil Polar Lipids on a Normal Phase  $\text{NH}_2$  Column.** Even though the separation of polar lipids on an SCX column results in excellent purification of the majority of phospholipids, some of them such as phosphatidylinositol (PI) and phosphatidylserine (PS) as well as phosphoglycolipids are not well separated.

For this purpose, a separation on a normal phase  $\text{NH}_2$  column was also performed. Polar lipids from 100 mL of olive oil were also separated in a single step (Figure 3) on a normal phase  $\text{NH}_2$  column. The amount of polar lipid fraction was fractionated (37) in 21 sequential separations of 40  $\mu\text{L}$  each. Fractions of the same retention times from each separation were pooled together to give 26 fractions, which tested for their biological activities.

Six of the 26 fractions did not exhibit any biological activity on platelets. Seventeen caused inhibition of platelet aggregation against  $1 \times 10^{-11}$  M PAF and 0.025 unit/cuvette thrombin. Three fractions (fractions 23, 25, and 26) caused aggregation of the platelets. The results are shown in Table 5. Fraction 23, which was the most active one exhibiting aggregatory activity, in the amount of 1789  $\mu\text{L}$  (initial volume of oil), desensitized  $1 \times 10^{-11}$  M PAF at 98%. The aggregatory activity is inhibited 96% by BN (specific inhibitor of PAF), 18% by indomethacin (specific inhibitor of thrombin), and 44% by the enzymatic system of creatine phosphate/creatine phosphate kinase (CP/CPK), which inhibits the aggregation caused by the possible ADP secretion.


**Separation and Biological Activity of Olive Oil Glycolipids.** To separate the glycolipids from olive oil, the solvent front from the HPLC separation of polar lipids (Figure 2) was further fractionated by HPLC (38) (Figure 4). The amount of glycolipid fraction was evaporated in a vacuum on a rotary evaporator and diluted in chloroform/methanol (1:1). It was then fractionated in seven sequential separations of 18  $\mu\text{L}$  each. Fractions of the same retention times from each separation were pooled together to give 14 fractions, which were tested for their biological activities.

Twelve of the 14 fractions caused inhibition of platelet aggregation against  $1 \times 10^{-11}$  M PAF (final concentration). The results are shown in Table 6.

Fractions 9 and 12, which caused aggregation of the platelets in an amount of 900  $\mu\text{L}$  (initial volume of oil), desensitized  $1 \times 10^{-11}$  M PAF (final concentration) at 100 and 92%, respectively.

**Separation and Biological Activity of Olive Oil Neutral Lipids.** To separate neutral lipids from olive oil, the total neutral lipid extract from the modified countercurrent distribution was combined with the solvent front from the HPLC separation of glycolipids (Figure 4). This fraction was evaporated in a vacuum rotary evaporator and diluted up to 13 mL with chloroform/methanol (1:1). An amount of 1 mL of this fraction was diluted up to 3 mL, and 81  $\mu\text{L}$  from this fraction was subjected to nine sequential separations by HPLC (39) (Figure 5). Fractions of the same retention times from each separation were pooled together to give 29 fractions, which tested for their biological activities.

Five of the 29 fractions (fractions 1, 2, 7, 8, and 13) did not exhibit any biological activity. The other fractions caused inhibition of platelet aggregation against  $1 \times 10^{-11}$  M PAF. The results are shown in Table 7. Seven fractions (fractions 10, 14–16, 24, 27, and 28) that were the most potent PAF inhibitors were also tested for their inhibitory activity against thrombin-induced washed rabbit platelet aggregation. The results



**Figure 3.** Representative HPLC chromatogram of total polar lipids (TPL) from olive oil on a normal phase NH<sub>2</sub> column. Conditions and elution of polar lipid standards as well as the solvent gradient used were as indicated. A, acetonitrile/methanol (70:30 v/v); B, methanol (100%); C, water (100%); Cer, ceramides; CB, cerebrosides; PC, phosphatidylcholine; SM, sphingomyelin; PAF, platelet activating factor; LPC, lysophosphatidylcholine; DGDG, digalactosyldiglycerides; PE, phosphatidylethanolamine; numbers 1–26 refer to the collected fractions.

**Table 5.** IC<sub>50</sub> and C<sub>PAF</sub> Values of Total Polar Lipid Fractions from Olive Oil after Separation on a Normal Phase NH<sub>2</sub> Column


polar lipid fraction	IC <sub>50PAF</sub> <sup>a</sup>	IC <sub>50Thr</sub> <sup>b</sup>	standards eluted in the same time
1	493	287	same as Cer <sup>c</sup>
2	5211	1270	same as Cer
3	6632	6632	same as CB <sup>d</sup>
4	19326	8202	same as CB
5	6158	11748	same as CB
6	1895	18950	same as CB
8	3432	6021	before PC <sup>e</sup>
12	4263	4058	same as PAF <sup>f</sup>
13	1253	4922	same as PAF
14	4168	5262	after PAF
15	1680	10400	before LPC <sup>g</sup>
17	12347	nd <sup>h</sup>	before LPC
18	5368	8678	same as LPC
19	10442	nd	same as LPC
20	3541	nd	same as LPC
21	2779	4969	same as DGDG <sup>i</sup>
22	5495	4264	after DGDG


polar lipid fraction	μL	C <sub>PAF</sub> <sup>j</sup>	standards eluted in the same time
23	1789	13.1	same as PE <sup>k</sup>
25	2368	25.0	beyond PE
26	3789	3.20	beyond PE

<sup>a</sup> Values are expressed in microliters of initial volume of oil that induces 50% inhibition against 1 × 10<sup>-11</sup> M PAF, final concentration. <sup>b</sup> Values are expressed in microliters of initial volume of oil that induces 50% inhibition against thrombin 0.025 unit/cuvette, final concentration. <sup>c</sup> Ceramides. <sup>d</sup> Cerebrosides. <sup>e</sup> Phosphatidylcholine. <sup>f</sup> Platelet activating factor. <sup>g</sup> Lysophosphatidylcholine. <sup>h</sup> Not detected. <sup>i</sup> Digalactosyldiglycerides. <sup>j</sup> Concentration of PAF that exhibits the same aggregatory activity as indicated in table (in microliters) of initial volume of oil. <sup>k</sup> Phosphatidylethanolamine.

are shown in **Table 7**. Most of these fractions are also inhibitors of thrombin.



**Figure 4.** Representative HPLC chromatogram of glycolipids of olive oil on a silica column. Conditions and elution of glyco- and some phospholipid standards as well as the solvent gradient used were as indicated. A, acetonitrile (100%); B, methanol (100%); SULF, sulfatides; DGDG, digalactosyldiglycerides; GCB, galactocerebrosides; GANG, gangliosides; PS, phosphatidylserine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; NL, neutral lipids; numbers 1–14 refer to the collected fractions.



**Figure 5.** Representative HPLC chromatogram of total neutral lipids (TNL) of olive oil on a C-18 column. Conditions and elution of neutral lipid standards as well as the solvent gradient used were as indicated. A, methanol/water (80:20 v/v); B, acetonitrile/methanol (70:50); C, acetonitrile/tetrahydrofuran (99.5:0.5 v/v); D, 2-propanol/acetonitrile (99:1 v/v); MG, monoglycerides; RH, hydrocarbons; FA, fatty acids; FAL, fatty alcohols; VitE, vitamin E; BAL, batyl alcohol; FAME, fatty acid methyl esters; DG, diglycerides; TG, triglycerides; CE, cholesterol esters; numbers 1–28 refer to the collected fractions.

**Table 6.**  $IC_{50}$  and  $C_{PAF}$  Values of Glycolipid Fractions from Olive Oil

glycolipid fraction	$IC_{50}^a$	standards eluted in the same time
1	670	before SULF <sup>b</sup>
2	403	same as SULF
3	448	after SULF
4	174	between SULF and DGDG <sup>c</sup>
5	374	between SULF and DGDG
6	426	before DGDG
7	576	same as DGDG
8	517	between DGDG and GCB <sup>d</sup>
10	100	between GANG <sup>e</sup> and PS <sup>f</sup>
11	590	between PS and PE <sup>g</sup>
13	830	same as PI <sup>h</sup>
14	270	beyond PI

glycolipid fraction	initial vol ( $\mu$ L)	$C_{PAF} \times 10^{-11} M^i$	standards eluted in the same time
9	900	2	same as GCB
12	900	2	same as PE

<sup>a</sup> Values are expressed in  $\mu$ L of initial volume of oil which induces 50% inhibition against  $1 \times 10^{-11}$  M PAF, final concentration. <sup>b</sup> Sulfatides. <sup>c</sup> Digalactosyldiglycerides. <sup>d</sup> Galactocerebrosides. <sup>e</sup> Gangliosides. <sup>f</sup> Phosphatidylserine. <sup>g</sup> Phosphatidylethanolamine. <sup>h</sup> Phosphatidylinositol. <sup>i</sup> Concentration of PAF that exhibits the same aggregatory activity as indicated in table (in microliters) of initial volume of oil.

Fraction 4, which was coeluted with fatty acids, was the only one that caused platelet aggregation. This fraction, in an amount of 1.35  $\mu$ L (initial volume of oil), exhibited the same aggregatory activity with  $6.8 \times 10^{-11}$  M PAF (final concentration). The same quantity desensitized  $1 \times 10^{-11}$  M PAF at 52%. The aggregatory activity is inhibited 100% by BN (specific inhibitor of PAF) and 44% by the enzymatic system of CP/CPK, which inhibits aggregation caused by the possibly secreted ADP.

**Structural Studies.** An attempt to elucidate the structure of fraction 23 from the separation of total polar lipids from olive oil was made using chemical determinations, biological tests, and electrospray mass spectrometry (ES-MS). Sugar determi-

nation was positive (0.540  $\mu$ mol of glucose/total fraction), whereas phosphorus determination was negative. To gain additional information about the structure of this bioactive lipid fraction, we examined the effect of human serum PAF-acetylhydrolase on the ability of the fraction to induce platelet aggregation. PAF-acetylhydrolase affected the biological activity of this fraction in an unusual way as the activity disappeared in the first 3 min while increasing gradually after a period of 6 min of treatment. It should also be noted that the final aggregation pattern after 12 min of treatment with PAF-acetylhydrolase was different from the original one. These results indicated the existence of two types of esterified acetic groups (44), on this molecule, that play a significant but controversial role in the biological activity.


The aggregation curve pattern from this fraction was different (long-standing with slight slope) from the one of PAF (short-standing with sharp slope). After alkaline hydrolysis, the chloroform phase exhibited a different aggregatory activity because its pattern was similar to the one of PAF. On the other hand, the water phase was not active. The reacetylation of the water phase was also not active. These results, which are in accordance with the ones from PAF-acetylhydrolase treatment, indicated the existence of ester bonds because alkaline hydrolysis results in a fat-soluble molecule with significant biological activity, even though different from the initial. Furthermore, reacetylation of the chloroform phase resulted in a molecule with a smaller activity. Also, acetylation of the initial intact compound resulted in a compound that presented decreased biological activity. This activity was identical to that of the reacetylated chloroform phase. Both data show that the existence of free hydroxyl groups plays a pivotal biological role. These findings suggest also that an ether bond as well as free hydroxyl group(s) exists in the molecule. The above shows that the ratio of acetyl to hydroxyl groups is important for the exhibition of the biological activity of the molecule and also that the esterified acid is the acetic acid.

The above data along with ES-MS for sample 23 of olive oil polar lipids (Figure 6) support the structure of the glycerol

**Table 7.** IC<sub>50</sub> Values of Total Neutral Lipid Fractions from Olive Oil and Their Percent Inhibition against Thrombin 0.025 Unit/Cuvette

neutral lipid fraction	IC <sub>50</sub> PAF <sup>a</sup>	% inhibition of thrombin <sup>b</sup>	standards eluted in the same time	neutral lipid fraction	IC <sub>50</sub> PAF	% inhibition of thrombin <sup>a</sup>	standards eluted in the same time
3	3.61		same as RH <sup>c</sup>	18	1.15		same as TG <sup>d</sup>
5	5.87		same as FAL <sup>e</sup>	19	6.21		same as TG
6	4.52		same as VitE <sup>f</sup>	20	2.84		after TG
9	3.10		same as DG <sup>g</sup>	21	2.80		after TG
10	0.36	57	same as DG	22	2.19		between TG and CE <sup>h</sup>
11	3.27		after DG	23	1.49		same as CE
12	2.90		between DG and TG	24	0.84	0	after CE
14	0.20	61	between DG and TG	25	3.04		beyond CE
15	0.95	51	between DG and TG	26	4.63		beyond CE
16	0.20	74	between DG and TG	27	0.74	26	beyond CE
17 <sub>1</sub>	1.53		before TG	28	0.27	79	beyond CE
17 <sub>2</sub>	1.75		same as TG				

<sup>a</sup> Values are expressed in microliters of initial volume of oil that induces 50% inhibition against  $1 \times 10^{-11}$  M PAF, final concentration. <sup>b</sup> Percent inhibition of thrombin was tested for the fractions with the most potent inhibitory effect of PAF action against washed rabbit platelets in an amount equal to C<sub>50</sub> of PAF. <sup>c</sup> Hydrocarbons. <sup>d</sup> Triglycerides. <sup>e</sup> Fatty alcohols. <sup>f</sup> Vitamin E. <sup>g</sup> Diglycerides. <sup>h</sup> Cholesterol esters.

**Figure 6.** Positive and negative ES-MS of sample 23 from olive oil polar lipids.

glycolipid compound shown in **Figure 8** with a molecular weight equal to  $m/z$  1789, along with its MS fragmentation.

Furthermore, the more abundant ion at  $m/z$  326 (**Figure 8**) represents the terminal sugar moiety, whereas the sodiated molecule yields the ion at  $m/z$  348. The deacylation of the terminal sugar moiety yields the negative ion at  $m/z$  281. Loss of the terminal sugar moiety gives rise to the positive ion at  $m/z$  1450. The  $m/z$  values of the positive ions at  $m/z$  623, 603, and 587 along with the abundant negative ion at  $m/z$  563 correspond to the fragment that contains the two terminal sugar moieties. The tandem mass spectrum (**Figure 7**) after collisionally activated dissociation of the parent ion at  $m/z$  563 contains only the ion at  $m/z$  281, which represents the deacetylated terminal sugar moiety as well as the other sugar moiety. Even more, loss of this fragment gives rise to the positive and negative

ions at  $m/z$  1169 and 1167, respectively. The structure of the fragment containing the three terminal sugar moieties is supported by positive ions at  $m/z$  911, 905, and 885 as well as by the negative ion at  $m/z$  845. Loss of the three terminal sugar moieties results in the positive and negative ions at  $m/z$  903 and 901, respectively. The fragment containing all four sugar moieties gives rise to the positive and negative ions at  $m/z$  1152 and 1128, respectively. Finally, the positive and negative ions at  $m/z$  1732 and 1730, respectively, correspond to the loss of the *sn*-2 acetic acid,  $[M + H - 58]^+$  and  $[M - H - 58]^-$ .

In this work we developed a modified countercurrent distribution for the separation of total lipids (TL) of vegetable oils to total polar lipids (TPL) and total neutral lipids (TNL). Biological activities of TL, TNL, and TPL lipids of several olive and seed oils were evaluated. The results showed that the





- (2) Parthasarathy, S.; Khoo, J. C.; Miller, E.; Barnett, J.; Witztum, J. L.; Steinberg, D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. *Proc. Natl. Acad. Sci. U.S.A.* **1990**, *87*, 3894–3898.
- (3) Bonanome, A.; Pagnan, A.; Biffanti, S.; Opportuno, A.; Sorgato, F.; Dorella, M.; Maiorino, M.; Ursini, F. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. *Arterioscler. Thromb.* **1992**, *12* (4), 529–533.
- (4) Keys, A. Coronary heart disease in Seven Countries. *Circulation* **1970**, *41* (Suppl. 1), 163–168.
- (5) Keys, A.; Anderson, J. T.; Grande, F. Serum response to changes in the diet. IV. Particular saturated fatty acids in the diet. *Metabolism* **1965**, *14*, 776–787.
- (6) Hegsted, D. M.; McGrundy, R. B.; Myers, M. L.; State, F. J. Quantitative effects of dietary fat on serum cholesterol in man. *Am. J. Clin. Nutr.* **1965**, *17*, 281–295.
- (7) Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N. Engl. J. Med.* **1989**, *320*, 915–924.
- (8) Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* **1993**, *362*, 801–809.
- (9) Ross, R. Cell biology of atherosclerosis. *Annu. Rev. Physiol.* **1995**, *57*, 791–804.
- (10) Demopoulos, C. A.; Pinckard, R. N.; Hanahan, D. J. Platelet-Activating Factor. Evidence for 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). *J. Biol. Chem.* **1979**, *254*, 9355–9358.
- (11) Antonopoulou, S.; Demopoulos, C. A. On the Mediterranean Diet. *Int. News Fats, Oils Relat. Mater.* **1997**, *8*, 776–777.
- (12) Liapikos, T. A.; Antonopoulou, S.; Karabina, S.-A. P.; Tsoukatos, D. C.; Demopoulos, C. A.; Tselepis, A. D. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. *Biochim. Biophys. Acta* **1994**, *1212*, 353–360.
- (13) Mueller, H. W.; Haught, C. A.; McNatt, J. M.; Cui, K.; Gaskell, S. J.; Johnston, D. A.; Willerson, J. T. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. *Circ. Res.* **1995**, *77* (1), 54–63.
- (14) Feliste, R.; Perret, B.; Braquet, P.; Chap, H. Protective effect of BN 52021, a specific antagonist of platelet-activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta. *Atherosclerosis* **1989**, *78*, 151–158.
- (15) Subbanagounder, G.; Leitinger, N.; Shih, P. T.; Faull, K. F.; Berliner, J. A. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. *Circ. Res.* **1999**, *85* (4), 311–318.
- (16) Choudhury, N.; Tan, L.; Truswell, A. S. Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. *Am. J. Clin. Nutr.* **1995**, *61*, 1043–1051.
- (17) Montedoro, G. F.; Servili, M.; Baldioli, M.; Miniati, E. Simple and hydrolyzable phenolic compounds in virgin olive oil. I. Their extraction, separation, and quantitative and semiquantitative evaluation by HPLC. *J. Agric. Food Chem.* **1992**, *40*, 1571.
- (18) Tiscornia, E.; Forina, M.; Evangelisti, F. Composizione chimica dell'olio di oliva e sue variazioni indotte dal processo di rettificazione. *Riv. Ital. Sostanze Grasse* **1982**, *54*, 519.
- (19) Covas, M. I.; Fito, M.; Lamuela-Raventos, R. M.; Sebastia, N.; de la Torre-Boronat, C.; Marrugat, J. Virgin olive oil phenolic compounds: binding to human low density lipoprotein (LDL) and effect on LDL oxidation. *Int. J. Clin. Pharmacol. Res.* **2000**, *20* (3–4), 49–54.
- (20) Lemcke-Norojarvi, M.; Kamal-Eldin, A.; Appelqvist, L. A.; Dimberg, L. H.; Ohrvall, M.; Vessby, B. Corn and sesame oils increase serum gamma-tocopherol concentrations in healthy Swedish women. *J. Nutr.* **2001**, *131*(4), 1195–201.
- (21) Visioli, F.; Galli, C. Antiatherogenic components of olive oil. *Curr. Atheroscler. Rep.* **2001**, *3*(1), 64–7.
- (22) Ahrens, E. H.; Insull, W.; Bromstrand, R.; Hirsch, J.; Tsaltas, T. T.; Peterson M. W. Influence of dietary fats on serum lipid levels in man. *Lancet* **1957**, 943–953.
- (23) Keys, A.; Anderson, J. T.; Grande, F. Prediction of serum cholesterol responses of man to change in fats in the diet. *Lancet* **1957**, *2*, 959–966.
- (24) Mattson, F. H.; Grundy, S. M. Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. *J. Lipid Res.* **1985**, *26* (2), 194–202.
- (25) Tyroler, H. A. lowering plasma cholesterol levels decreases risk of coronary heart disease: an overview of clinical trials. In *Hypercholesterolemia and Atherosclerosis*; Steinberg, D., Olefsky, J. M., Eds.; Churchill Livingstone: New York, 1987; pp 99–116.
- (26) Steinberg, M. B.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. Modifications of low-density lipoprotein that increase its atherogenicity. *New Engl. J. Med.* **1987**, *320*, 915–924.
- (27) Renaud, S.; De Lorgeril, M.; Delaye, J.; Guidollet, J.; Jacquard, F.; Mamelle, N.; Martin, J. L.; Monjaud, I.; Salen, P.; Touboul, P. The Cretan Mediterranean diet for prevention of coronary heart disease. *Am. J. Clin. Nutr.* **1995**, *61* (Suppl.), 1360S–1367S.
- (28) Koussissis, S. G.; Semidalas, C. E.; Antonopoulou, S.; Kapoulas, V. M.; Demopoulos, C. A.; Kalyvas, V. PAF antagonists in foods: Isolation and identification of PAF in virgin olive oil. *Rev. Fr. Corp Gras* **1993**, *40*, 323–327.
- (29) Koussissis, S. G.; Semidalas, C. E.; Hadzistavrou, E. C.; Kalyvas, V.; Antonopoulou, S.; Demopoulos, C. A. PAF antagonists in foods: Isolation and identification of PAF in honey and wax. *Rev. Fr. Corp Gras* **1994**, *41*, 127–132.
- (30) Antonopoulou, S.; Semidalas, C. E.; Koussissis, S. G.; Demopoulos, C. A. Platelet-Activating Factor (PAF) antagonists in foods. A study of lipids, with PAF or anti-PAF like-activity, in cow's milk and yoghurt. *J. Agric. Food Chem.* **1996**, *44*, 3047–3051.
- (31) Rementzis, J.; Antonopoulou, S.; Demopoulos, C. A. Identification and study of gangliosides from *Scomber scombrus* muscles. *J. Agric. Food Chem.* **1997**, *45*, 611–615.
- (32) Fragopoulou, E.; Nomikos, T.; Antonopoulou, S.; Mitsopoulou, C. A.; Demopoulos, C. A. Separation of biologically active lipids from red wine. *J. Agric. Food Chem.* **2000**, *48*, 1234–1238.
- (33) Stafforini, D. M.; McIntyne, T. M.; Carter, M. E.; Prescott, S. M. Human plasma platelet-activating factor acetylhydrolase. *J. Biol. Chem.* **1987**, *262*, 4223–4230.
- (34) Galanos, D. S.; Kapoulas, V. M. Isolation of polar lipids from triglyceride mixtures. *J. Lipid Res.* **1962**, *3*, 134–137.
- (35) Craig, L. C.; Craig, D. In *Technique of Organic Chemistry*; Interscience Publishers: New York, 1950; Vol. 3, p 171.
- (36) Andrikopoulos, N. K.; Demopoulos, C. A.; Siafaka-Kapadai, A. High-performance liquid chromatographic analysis of platelet-activating factor on a cation-exchange column by direct ultra-violet detection. *J. Chromatogr.* **1986**, *363*, 412–417.
- (37) Nomikos, T.; Karantonis, H. C.; Fragopoulou, E.; Demopoulos, C. A. One step separation system for the main phospholipids, glycolipids and phenolics by normal phase HPLC. Application to polar lipid extracts from olive and sunflower olive. *J. Liq. Chromatogr. Relat. Technol.* **2002**, in press.
- (38) Demopoulos, C. A.; Kyrili, M.; Antonopoulou, S.; Andrikopoulos, N. K. Separation of several main glycolipids into classes and partially into species by HPLC and UV-detection. *J. Liq. Chromatogr. Relat. Technol.* **1996**, *19* (5), 771–781.
- (39) Antonopoulou, S.; Andrikopoulos, N. K.; Demopoulos, C. A. Separation of the main neutral lipids into classes and species by PR-HPLC and UV detection. *J. Liq. Chromatogr.* **1994**, *17*, 633–648.
- (40) Lazanas, M.; Demopoulos, C. A.; Tourmis, S.; Koussissis, S.; Labrakis-Lazanas, K.; Tsarouzas, X. PAF of biological fluids

- in disease IV. Levels in blood in allergic reactions induced by drugs. *Arch. Dermatol. Res.* **1988**, *280*, 124–126.
- (41) Bligh, E. G.; Dyer, W. J. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **1959**, *37*, 911–917.
- (42) Bartlett, G. R. Phosphorus assay in column chromatography. *J. Biol. Chem.* **1959**, *234*, 466–468.
- (43) Galanos, D. S.; Kapoulas, V. M. Preparation and analysis of lipid extracts from milk and other tissues. *Biochim. Biophys. Acta* **1965**, *98*, 278–292.
- (44) Demopoulos, C. A.; Antonopoulou, S. A discovery trip to compounds with PAF-like activity. *Adv. Exp. Med. Biol.* **1996**, *416*, 59–63.

---

**Received for review July 17, 2001. Revised manuscript received October 30, 2001. Accepted November 1, 2001. This research was supported in part by SEVITEL.**

JF010923T